Review of: "Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases"

Ghulam Abbas[1]

1 Riphah International Univeristy

Potential competing interests: No potential competing interests to declare.

It is reported that more than 200 viruses can infect humans, whereas for less than ten of them, treatments are available. Traditional therapies adhere to a '**one drug, one bug**' model wherein a drug is developed to target one function within a specific virus. Viral superinfection therapy activates the interferon genes' natural, antiviral defense system of host cells following exposure to viral infection. This research focuses on dsRNA IBDV as a simple and cost-effective therapy against viral illnesses. Acid-resistant IBDV can be orally administered in an outpatient setting, providing simple dosing and high medication adherence. The IBDV drug can be used in treating millions of early-stage patients with COVID-19 and many other viral illnesses.

This manuscript is accepted as it is